

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

UNAUDITED RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2011
CONSOLIDATED INCOME STATEMENT

		(Unaudited)	
		3 months ended 31 March	
	<i>NOTES</i>	2011	2010
		<i>HK\$'000</i>	<i>HK\$'000</i>
			<i>(Restated)</i>
Direct expenses			
		28,623d)	



CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(Unaudited)
3 months ended 31 March
2011 **2010**
HK\$'000 ***HK\$'000***

Profit for the period

33,609 **23,330**

NOTES TO THE UNAUDITED RESULTS

1. BASIS OF PREPARATION AND PRINCIPAL ACCOUNTING POLICIES

The unaudited results for the three months ended 31 March 2011 have been prepared in accordance with accounting principles generally accepted in Hong Kong and Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants. The unaudited results should be read in conjunction with the 2010 annual report. The audit committee of the Company, which consists of three

During the year ended 31 December 2010, the IRD further issued protective profits tax assessments of approximately HK\$5,250,000 to that subsidiary of the Company relating to the year of assessment 2003/04,

5. EARNINGS PER SHARE

The calculation of the basic and diluted earnings per share attributable to the owners of the Company is based on the following data:

	(Unaudited)	
	3 months ended 31 March	
	2011	2010
	<i>HK\$'000</i>	<i>HK\$'000</i>
Earnings		
Profit for the period attributable to the owners of the Company of the purposes of basic and diluted earnings per share	32,836	22,612
Numbers		
Weighted average number of ordinary shares for the purpose of basic earnings per share	1,551,056,993	1,551,056,993
Effect of dilutive ordinary shares in respect of share options	7,063,846	(2,522,036)

BUSINESS REVIEW

For the first quarter of 2011, in regard to the uncertainties of renewing the import drug license of “Osteoform calcium amino acid chelate capsule”, the Group has received a written notification from Pharmco International, Inc, the sole supplier of Osteoform Compound Calcium Amino Acid Chelate Capsules in January 2011. In the written notice, it was mentioned that Pharmco was notified by the Department of Drug Registration of the State Food and Drug Administration in the PRC that they intend to issue a notice of non-renewal of import drug license of Osteoform to Pharmco in the near future. Despite the uncertainties, the Group continues to diversify product and business development, expand and optimize product

“Osteoform Vitamins with minerals dispersible tablet”, a compound vitamin and minerals product

